Litcius/Paper detail

KPC-Mediated Resistance to Ceftazidime-Avibactam and Collateral Effects in Klebsiella pneumoniae

Jacqueline Findlay, Laurent Poirel, Mario Juhas, Patrice Nordmann

2021Antimicrobial Agents and Chemotherapy72 citationsDOIOpen Access PDF

Abstract

selection assays were conducted, resulting in the identification of a series of mutations in the KPC sequence which conferred the ability of those mutated enzymes to confer resistance to CZA. Hence, 16 KPC-2 variants and 10 KPC-3 variants were obtained. Production of the KPC variants in an Escherichia coli recombinant strain resulted in a concomitant increased susceptibility to broad-spectrum cephalosporins and carbapenems, with the exceptions of ceftazidime and piperacillin-tazobactam, compared to wild-type KPC enzymes. Enzymatic assays showed that all of the KPC variants identified exhibited an increased affinity toward ceftazidime and a slightly decreased sensitivity to avibactam, sustaining their impact on CZA resistance. However, their respective carbapenemase activities were concurrently negatively impacted.

Topics & Concepts

Ceftazidime/avibactamKlebsiella pneumoniaeCeftazidimeMicrobiologyAvibactamMedicineBeta-lactamBeta-Lactamase InhibitorsBiologyAntibioticsBacteriaPseudomonas aeruginosaEscherichia coliGeneticsGeneAntibiotic Resistance in BacteriaPneumocystis jirovecii pneumonia detection and treatmentCancer therapeutics and mechanisms